Xinhua Full Media+丨 The 7th Batch of National Organization Drug Collection Detaispin 48% of the price reduction price is 48%

On July 12, the seventh batch of national organizational drug concentrated procurement site. Xinhua News Agency reporter Qiu Bingqing Photo

Xinhua News Agency, Nanjing, July 12 (Reporter Peng Yunjia and Qiu Bingqing) The seventh batch of national organizational drugs were purchased on the 12th. The collection of 60 drugs in the collection is successful, and the average price reduction of 327 selected products is 48%. According to the agreed purchase volume, it is expected to save 18.5 billion yuan per year.

This time the collection of drugs involved 31 treatment categories, including common diseases such as hypertension, diabetes, anti -infection, digestive tract diseases, and major diseases such as lung cancer, liver cancer, kidney cancer, and bowel cancer. Get strong. Taking the first -line liver cancer -targeted Yaolunbutoni capsule as an example, each one drops from 108 yuan to an average of 18 yuan, and a treatment cycle can save 8,100 yuan. For the first time in the field of lowering blood pressure, it was included in the slow -controlled release agent. The price of nifeding horizontal control was 58%reduced, and the price of Matolol's slow -release tablet was 53%. The burden on the medication of patients with hypertension was significantly reduced.

In addition, Pfizer's Donalin, Japan's Anstelai Mikafen Pure, Emmiro of Spain, Emmoro, and Bryko Xinyi, Italy, 4 original research medicines In the election, the average price was reduced by 67%.

In terms of procurement rules, this collection adheres to the basic principles of "linked and price linked, recruiting one" and "national organization, alliance procurement, platform operation" working mechanism, and make further adjustments and optimizations, strengthen supply guarantees, such as introducing preparations, such as introducing preparations For the supply mechanism, each province will also have one main company and one to prepare for enterprises to ensure stable clinical use.

Since the establishment of the State Medical Insurance Administration, 7 batches of national organizational drugs have been carried out, covering a total of 294 kinds of drugs, and calculated by the pre -collection price, which involves about 35%of the procurement of chemical drugs and biopharmaceuticals in public medical institutions. Overseas procurement has become an important model for drug procurement of public hospitals.

In the next step, the National Medical Insurance Administration will work with relevant departments to guide the implementation of the selection results in various places and middle school companies to ensure that patients across the country use the selected products after the collection of prices in November 2022.

[Editor in charge: Xue Tao]

- END -